Jazz Pharmaceuticals (JAZZ) Running On Buy From Smart Investor
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Join SI Premium – FREE
Last night after the close, Patrick Enright bought 150,000 shares of Jazz Pharmaceuticals (Nasdaq: JAZZ) at around $7.21 a share. Patrick Enright is a Director at Jazz, but he is also a Managing Director at a biotech focused VC fund, Longitude Capital.
Enright serves also serves on Corcept Therapeutics (NASDAQ: CORT) board as well. He has previously served on the boards of Codexis, DiObex Pharmaceuticals, Horizon Therapeutics, MAP Pharmaceuticals (NASDAQ: MAPP), Prestwick Pharmaceuticals, Threshold Pharmaceuticals (NASDAQ: THLD) and Sequenom (NASDAQ: SQNM).
Jazz Pharmaceuticals has been a momentum stock and has risen over 700% since early June and is trading up approximately 20% today to $8.43.
Enright serves also serves on Corcept Therapeutics (NASDAQ: CORT) board as well. He has previously served on the boards of Codexis, DiObex Pharmaceuticals, Horizon Therapeutics, MAP Pharmaceuticals (NASDAQ: MAPP), Prestwick Pharmaceuticals, Threshold Pharmaceuticals (NASDAQ: THLD) and Sequenom (NASDAQ: SQNM).
Jazz Pharmaceuticals has been a momentum stock and has risen over 700% since early June and is trading up approximately 20% today to $8.43.
You May Also Be Interested In
Create E-mail Alert Related Categories
Insider Trades, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
